LINC00511 Knockdown Suppresses Resistance to Cisplatin in Lung Adenocarcinoma by Interacting with miR-182-3p and BIRC5.

Abstract

We studied the role of long intergenic non-protein coding RNA 00,511 (LINC00511) in lung adenocarcinoma (LUAD), with a specific focus on acquired chemoresistance. LINC00511 expression was higher in responders to cisplatin (DDP, another name for cisplantin) than non-responders, in A549/DDP cells than in parental A549 cells and normal human bronchial epithelial cells (16HBE). LINC00511 knockdown decreased the half maximal inhibitory concentration (IC50) value, suppressed A549/DDP cell viability, but induced apoptosis. LINC00511 bound with miR-182 and increased the expression of baculoviral inhibitor of apoptosis protein (IAP) repeat containing 5 (BIRC5). BIRC5 knockdown mimicked the effects of LINC00511 knockdown on the IC50 value, A549/DDP cell viability, and apoptosis. BIRC5 overexpression negated the effects of LINC00511 knockdown on A549/DDP cells. In vivo, LINC00511 knockdown attenuated the tumorigenesis of A549/DDP cells after DDP injection. These results provide a novel LINC00511/miR-182/BIRC5 paradigm to explain the mechanism of acquired DDP resistance.

• Authors: Zhongcheng Zhu, Yufeng Shi, Xiaoyi Gong, Jing Li, Mingyun Zhang
• Journal: Molecular biotechnology (Mol Biotechnol) Vol. 64 Issue 3 Pg. 252-262 (Mar 2022) ISSN: 1559-0305 [Electronic] Switzerland
• PMID: 34595724 (Publication Type: Journal Article)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Chemical References

• BIRC5 protein, human
• MicroRNAs
• Mirn182 microRNA, human
• RNA, Long Noncoding
• RNA, Small Interfering
• Survivin
• Cisplatin

Topics

• A549 Cells
• Adenocarcinoma of Lung (drug therapy, genetics)
• Animals
• Cell Line, Tumor
• Cisplatin (administration & dosage, pharmacology)
• Down-Regulation
• Drug Resistance, Neoplasm (drug effects)
• Female
• Gene Expression Regulation, Neoplastic (drug effects)
• Humans
• Male
• Mice
• MicroRNAs (genetics)
• RNA, Long Noncoding (antagonists & inhibitors, genetics)
• RNA, Small Interfering (administration & dosage, pharmacology)
• Survivin (genetics)
• Up-Regulation (drug effects)
• Xenograft Model Antitumor Assays